Keith Alkek, CBO & Co-Founder Thirty-year career in biopharmaceuticals, in niche products and rare diseases, has launched a variety of treatments and developed innovative approaches to improve diagnostics and to support overall comprehensive care for those with rare diseases.
Alice McConnell, CEO & Co-Founder is a former Civil Engineer, who administered private and government contracts, designed, planned, coordinated, scheduled, estimated, met regulatory compliance, and managed large complex multi-year engineering projects.
Hope for Rare Disorders
Speragen was cofounded by a mother of two children who are affected with a rare disease, Succinic Semialdehyde Dehydrogenase (SSADH) deficiency. Speragen knows first-hand the challenges of navigating a life with a rare disease: from the daily challenges, the diagnostic odyssey, accepting the new reality post-diagnosis, finding a team of knowledgeable clinicians who can provide care, and finally to seeing the chasm between the current state treatment and when a therapy may be available. Speragen, comes from the Latin word “spera” meaning “hope”, was formed to help solve these issues more rapidly by bridging the gulf from hope to the realization of a therapy.